Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
Authors not listed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2001
Abstract
The purpose of this study is to evaluate the safety and effectiveness of a once daily controlled-release form of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-10 MST
Cite this
APA
Anonymous. (2001). Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation. <em>Johnson & Johnson Pharmaceutical Research & Development, L.L.C.</em>. https://clinicaltrials.gov/study/NCT00253214
Vancouver
Anonymous. Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation. Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 2001.
BibTeX
@misc{anon2001Placeb,
title = {Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation},
author = {Anonymous},
journal = {Johnson & Johnson Pharmaceutical Research & Development, L.L.C.},
year = {2001},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 1997
Open access · US-GOV
Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2000
Open access · US-GOV
Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.
Federal University of Minas Gerais 2013
Open access · US-GOV
Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease: a Randomised, Double-blind, Controlled Study
Ali Rezai, MD 2012
Open access · US-GOV
Deep Brain Stimulation (DBS) for Treatment of the Cognitive, Behavioral, and Functional Disability of Alzheimer's Disease
AstraZeneca 2016
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
JHSPH Center for Clinical Trials 2009
Open access · US-GOV